[go: up one dir, main page]

DE69025933D1 - Verwendung von alpha-d-galactosidase zur herstellung einer pharmazeutischen zusammensetzung zur linderung von gastro-intestinalen beschwerden durch alpha-d-galactosid gebundene zucker. - Google Patents

Verwendung von alpha-d-galactosidase zur herstellung einer pharmazeutischen zusammensetzung zur linderung von gastro-intestinalen beschwerden durch alpha-d-galactosid gebundene zucker.

Info

Publication number
DE69025933D1
DE69025933D1 DE69025933T DE69025933T DE69025933D1 DE 69025933 D1 DE69025933 D1 DE 69025933D1 DE 69025933 T DE69025933 T DE 69025933T DE 69025933 T DE69025933 T DE 69025933T DE 69025933 D1 DE69025933 D1 DE 69025933D1
Authority
DE
Germany
Prior art keywords
alpha
galactoside
galactosidase
tied
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69025933T
Other languages
English (en)
Other versions
DE69025933T3 (de
DE69025933T2 (de
Inventor
Alan Kligerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Block Drug Co Inc
Original Assignee
Akpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23385155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69025933(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akpharma Inc filed Critical Akpharma Inc
Publication of DE69025933D1 publication Critical patent/DE69025933D1/de
Application granted granted Critical
Publication of DE69025933T2 publication Critical patent/DE69025933T2/de
Publication of DE69025933T3 publication Critical patent/DE69025933T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69025933T 1989-05-16 1990-05-10 Verwendung von alpha-d-galactosidase zur herstellung einer pharmazeutischen zusammensetzung zur linderung von gastro-intestinalen beschwerden durch alpha-d-galactosid gebundene zucker. Expired - Lifetime DE69025933T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35244189A 1989-05-16 1989-05-16
PCT/US1990/002643 WO1990014101A1 (en) 1989-05-16 1990-05-10 Composition and method for reducing gastro-intestinal distress due to alpha-d-galactoside-linked/containing sugars

Publications (3)

Publication Number Publication Date
DE69025933D1 true DE69025933D1 (de) 1996-04-18
DE69025933T2 DE69025933T2 (de) 1996-09-05
DE69025933T3 DE69025933T3 (de) 2002-09-05

Family

ID=23385155

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69025933T Expired - Lifetime DE69025933T3 (de) 1989-05-16 1990-05-10 Verwendung von alpha-d-galactosidase zur herstellung einer pharmazeutischen zusammensetzung zur linderung von gastro-intestinalen beschwerden durch alpha-d-galactosid gebundene zucker.

Country Status (17)

Country Link
US (3) US5989544A (de)
EP (1) EP0472588B2 (de)
JP (1) JPH0725695B2 (de)
KR (1) KR0178029B1 (de)
AT (1) ATE135165T1 (de)
AU (1) AU629941B2 (de)
CA (2) CA2329486C (de)
DE (1) DE69025933T3 (de)
DK (1) DK0472588T4 (de)
ES (1) ES2084696T5 (de)
FI (1) FI915402A0 (de)
GR (1) GR1000903B (de)
IE (1) IE81156B1 (de)
NZ (1) NZ233582A (de)
PE (1) PE2591A1 (de)
WO (1) WO1990014101A1 (de)
ZA (1) ZA903749B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436003A (en) * 1994-02-10 1995-07-25 Triarco Industries, Inc. Method of alleviating gastrointestinal distress with a composition containing beta-fructofuransidase, cellulase and hemi-cellulase
US6099844A (en) * 1994-08-22 2000-08-08 Triarco Industries, Inc. Increasing yield of extractable substances from botanicals with an enzyme composition
WO1997013526A1 (en) * 1995-10-10 1997-04-17 Novo Nordisk A/S Method of improving lipid digestion
ATE242605T1 (de) * 1998-06-24 2003-06-15 Sraum Di Ezio Bartocci E C S A Lebensmittel basierend auf cerealien, insbesondere für die menschliche ernährung
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US20060198934A1 (en) * 2005-03-01 2006-09-07 Ronald S.O. Zane Process for removing flatulence-associated oligosaccharides in legumes
JP2010517591A (ja) * 2007-02-14 2010-05-27 エー．ソロモン ネイル ラクターゼ配合物
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
ITMI20111154A1 (it) * 2011-06-24 2012-12-25 Promefarm Srl Composizioni farmaceutiche o nutrizionali comprendenti galattosidasi e loro uso
US20130084313A1 (en) * 2011-09-30 2013-04-04 Stomavite, Llc Supplement for ostomy patients
US9402885B2 (en) 2013-07-15 2016-08-02 Alfa Wassermann S.P.A. Method of treating GERD with alpha and beta galactosidases
AU2017269498A1 (en) * 2016-05-24 2018-11-08 Novozymes A/S Polypeptides having alpha-galactosidase activity and polynucleotides encoding same
AU2021310923A1 (en) * 2020-07-23 2023-02-09 Kiwi Health, Inc Food supplement composition to aid in digestion of fructan, mannitol, and sorbitol

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1008583A (en) * 1961-04-25 1965-10-27 Olin Mathieson Controlled release medicaments
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
US3479122A (en) 1967-04-05 1969-11-18 Takaji Funahashi Writing instrument
US3632346A (en) * 1968-04-30 1972-01-04 Rohm & Haas Process for rendering innocuous flatulence-producing saccharides
JPS4826978A (de) * 1971-08-12 1973-04-09
US3846239A (en) * 1972-07-24 1974-11-05 Monsanto Co Process for the preparation of heat-resistant alpha-galactosidase enzyme
US3795585A (en) † 1972-08-31 1974-03-05 Agency Ind Science Techn Method for manufacture of alpha-galactosidase
CH585793A5 (de) * 1974-02-01 1977-03-15 Nestle Sa
GB1446965A (en) * 1974-02-14 1976-08-18 Agricultural Vegetable Prod Preparation of food products
JPS5344556B2 (de) * 1974-03-18 1978-11-29
JPS5322158B2 (de) * 1974-05-02 1978-07-06
US4241185A (en) * 1979-02-23 1980-12-23 The Great Western Sugar Company Method of stabilizing α-galactosidase
IT1130242B (it) * 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4376127A (en) * 1981-01-23 1983-03-08 Lunde Kenneth E Process for deflatulating and improving the digestibility of legumes
JPS5843075B2 (ja) † 1981-03-03 1983-09-24 株式会社 林原生物化学研究所 α−Ｄ−ガラクトシダ−ゼの製造方法
JPS5843075A (ja) * 1981-09-09 1983-03-12 Canon Inc 印字装置付電子機器
EP0081261B1 (de) 1981-11-30 1986-10-15 Josep Ramisa Navarro Vorrichtung zur Zerstäubung von vernebeltem Wasser
IT1140312B (it) 1981-12-03 1986-09-24 Anic Spa Procedimento per la produzione di alfa-galattosidasi e impieghi dell'enzima cosi' ottenuto
US4861718A (en) * 1984-09-29 1989-08-29 Wakamoto Pharmaceutical Co., Ltd. Gene coding for thermostable beta-galactosidase, bacillus subtilis having the gene, enzyme coded by the gene and a process for the production thereof
DK80588A (da) 1987-02-23 1988-08-24 Suomen Sokeri Oy Fjerkrae-foder, fodringsmetode og fremgangsmaade til forbedring af fordoejeligheden af fjerkrae-foder
FR2611778B1 (fr) * 1987-02-26 1992-04-24 Paris Ouest Entreprise Plancher a collaboration bois-beton
FI78814C (fi) 1987-03-30 1989-10-10 Cultor Oy Nollfiber innehaollande foderraoaemne och foder samt foerfarande foer deras framstaellning.
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
FR2647638A1 (fr) 1989-05-30 1990-12-07 Euretec Gie Composition alimentaire contenant un enzyme
US5436003A (en) 1994-02-10 1995-07-25 Triarco Industries, Inc. Method of alleviating gastrointestinal distress with a composition containing beta-fructofuransidase, cellulase and hemi-cellulase

Also Published As

Publication number Publication date
CA2055506C (en) 2001-02-13
PE2591A1 (es) 1991-02-05
DK0472588T3 (da) 1996-04-01
ATE135165T1 (de) 1996-03-15
JPH05500043A (ja) 1993-01-14
DE69025933T3 (de) 2002-09-05
US5989544A (en) 1999-11-23
JPH0725695B2 (ja) 1995-03-22
CA2329486A1 (en) 1990-11-17
EP0472588A1 (de) 1992-03-04
EP0472588B1 (de) 1996-03-13
US20020106366A1 (en) 2002-08-08
GR900100374A (en) 1991-10-10
ES2084696T3 (es) 1996-05-16
US6344196B1 (en) 2002-02-05
AU629941B2 (en) 1992-10-15
EP0472588A4 (en) 1992-05-06
IE81156B1 (en) 2000-05-03
FI915402A0 (fi) 1991-11-15
WO1990014101A1 (en) 1990-11-29
KR920700680A (ko) 1992-08-10
IE901742L (en) 1990-11-16
ZA903749B (en) 1991-08-28
ES2084696T5 (es) 2002-08-16
NZ233582A (en) 1992-05-26
AU5640690A (en) 1990-12-18
KR0178029B1 (ko) 1999-03-20
DE69025933T2 (de) 1996-09-05
DK0472588T4 (da) 2002-02-18
CA2055506A1 (en) 1990-11-17
EP0472588B2 (de) 2002-01-02
GR1000903B (el) 1993-03-16
CA2329486C (en) 2004-11-02

Similar Documents

Publication Publication Date Title
DE69025933D1 (de) Verwendung von alpha-d-galactosidase zur herstellung einer pharmazeutischen zusammensetzung zur linderung von gastro-intestinalen beschwerden durch alpha-d-galactosid gebundene zucker.
Nagase Contribution to the physiology of digestion in Tilapia mossambica Peters: Digestive enzymes and the effects of diets on their activity
AU653026B2 (en) Physiologically active polypeptide-containing pharmaceutical composition
CA2271865A1 (en) Tablet composition
BR9507811B1 (pt) polipeptìdeos e composição farmacêutica.
GR3003402T3 (en) Vanadium-peroxide compositions as insulin mimickers
KR20030070029A (ko) 당뇨병 치료제
Wolever et al. Guar, but not psyllium, increases breath methane and serum acetate concentrations in human subjects
ES2097162T3 (es) Utilizacion de acidos grasos de cadena corta en alimentacion clinica.
SE8303401D0 (sv) Beredning och dess anvendning
IS5416A (is) Samsetning til að bæla fráhvarfseinkenni og fíkn í áfengi hjá áfengissjúklingum og fyrirbyggja misnotkun áfengis hjá heilbrigðum einstaklingum
Hewitt Addison's disease occurring in sisters
IL95046A0 (en) Substituted 2-imidazolines and pharmaceutical compositions containing them
DE69231583D1 (de) Zusammensetzung zur Behandlung des Insulinmangels bei Säugetieren, die Amylin und Insulin enthält.
ES8603755A1 (es) Un procedimiento para preparar un agente curativo y preventivo de ulceras a base de componentes de brotes de casia solubles en agua.
JPS649938A (en) Oral ingestive composition
Kemp The adrenal cortex
US6403560B1 (en) Immunopotentiator and method for preparing the same
Panda et al. A case study on the management of Garbhini Chardi wsr to Emesis Gravidarum
MD186C2 (ro) Metodă de tratament al endometritei după operaţia cezariană
Emerson Intestinal motility in rats anesthetized with ether
TAKAHASHI Transplacental effects of 3, 5-dimethyl-3′-isopropyl-L-thyronine on tubulin content in fetal brains in rats
KR100688213B1 (ko) 오징어 먹물을 이용한 오징어의 가공처리방법
Mann A Resume of Diabetes Mellitus
Hill Anaesthetic risks

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: BLOCK DRUG CO., INC., JERSEY CITY, N.J., US